Show simple item record

dc.contributor.authorSoran, Atilla
dc.contributor.authorBhargava, Rohit
dc.contributor.authorJohnson, Ronald
dc.contributor.authorAhrendt, Gretchen
dc.contributor.authorBonaventura, Marguerite
dc.contributor.authorDiego, Emilia
dc.contributor.authorMcAuliffe, Priscilla F.
dc.contributor.authorSerrano, Merida
dc.contributor.authorMenekşe, Ebru
dc.contributor.authorSezgin, Efe
dc.contributor.authorMcGuire, Kandace P.
dc.date.accessioned2017-06-28T08:03:31Z
dc.date.available2017-06-28T08:03:31Z
dc.date.issued2016
dc.identifier.citationSoran, A., Bhargava, R., Johnson, R., Ahrendt, G., Bonaventura, M., Diego, E., McAuliffe, P. F., Serrano, M., Menekşe, E., Sezgin, E., and McGuire, K. P. (2016). The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Disease, 36(2-3), 65-71. doi:10.3233/BD-150199en_US
dc.identifier.issn0888-6008
dc.identifier.urihttp://doi.org/10.3233/BD-150199
dc.identifier.urihttp://hdl.handle.net/11147/5793
dc.description.abstractBACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; 50%), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median %TR was 42 (0 97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.en_US
dc.language.isoengen_US
dc.publisherIOS Pressen_US
dc.relation.isversionof10.3233/BD-150199en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast canceren_US
dc.subjectEstrogen positiveen_US
dc.subjectTumor volume reductionen_US
dc.subject21 gene assayen_US
dc.subjectNeoadjuvant therapyen_US
dc.subjectAntineoplastic agenten_US
dc.titleThe impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast canceren_US
dc.typearticleen_US
dc.contributor.authorIDTR220177en_US
dc.contributor.iztechauthorSezgin, Efe
dc.relation.journalBreast Diseaseen_US
dc.contributor.departmentİYTE, Mühendislik Fakültesi, Gıda Mühendisliği Bölümüen_US
dc.identifier.volume36en_US
dc.identifier.issue2-3en_US
dc.identifier.startpage65en_US
dc.identifier.endpage71en_US
dc.identifier.scopusSCOPUS:2-s2.0-84988632525
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record